Drug Profile
Glesatinib companion diagnostic - Mirati Therapeutics/Foundation Medicine
Latest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Foundation Medicine
- Developer Foundation Medicine; Mirati Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Non-small cell lung cancer
Most Recent Events
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb
- 29 Aug 2019 Discontinued - Phase-II for Non-small cell lung cancer (Diagnosis, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Australia, South Korea (unspecified route)
- 21 Dec 2015 Mirati Therapeutics announces intention to submit PMA to the US FDA concurrent with the NDA filing for glesatinib